Peptide-Oleic Acid Complex for Selective Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bladder cancer therapies are limited by high recurrence rates and significant side effects, with a need for more selective and less toxic treatments that can effectively target tumor cells while sparing healthy cells.
Innovation Solution
A combination chemotherapy approach using a biologically active complex comprising a peptide with an alpha-helical structure and oleic acid or oleate salt, in conjunction with established chemotherapeutic agents like mitomycin C or epirubicin, to enhance tumor specificity and reduce toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If highly toxic substances are used to kill cancer cells, then tumor-killing efficacy is improved, but side effects on healthy cells increase
Solution Approach 1:
The biologically active complex is designed to specifically target and accumulate in tumor cells through interaction with tumor-specific membranes, creating localized high concentration of chemotherapeutic agents at the tumor site while maintaining low systemic concentration, thereby killing tumor cells effectively while sparing healthy cells
Solution Approach 2:
The biologically active complex acts as an intermediary carrier that binds chemotherapeutic agents and delivers them selectively to tumor cells. The complex consists of a peptide component that recognizes tumor cell surfaces and a lipid component that facilitates cellular uptake, mediating the delivery of toxic chemicals specifically to cancer cells
2Reliability
If conventional chemotherapeutic agents are used, then tumor cells are killed, but selectivity between tumor and healthy cells is insufficient
Solution Approach 1:
The complex exhibits tumor-specific localization properties through its peptide component that recognizes and binds to receptors overexpressed on tumor cell surfaces, creating a localized therapeutic effect exclusively at the tumor site while healthy cells lacking these receptors remain unaffected
Solution Approach 2:
The biologically active complex is a composite structure combining a peptide component for tumor-specific recognition and a lipid component for cellular membrane fusion and drug delivery, creating a multifunctional agent that provides both selectivity and efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy demonstrates enhanced antitumor activity by disrupting tumor membrane integrity and increasing the uptake of chemotherapeutic agents into tumor cells, leading to improved therapeutic effects with reduced side effects on healthy cells, as evidenced by murine bladder cancer model studies.
Implementation Method 1
the biologically active complexes according to the invention can disrupt tumor membrane integrity
Implementation Method 2
increase uptake of co-administered chemotherapeutic agents into the tumor cell and/or the tumor cell nucleus
Data Source
AI summary
A first chemotherapeutic agent and a second chemotherapeutic agent for use in cancer therapy, wherein the second chemotherapeutic agent comprises a biologically active complex having anti-tumour activity, wherein the biologically active complex consists of: a peptide of at least 10 amino acids comprising an alpha-helical structure; and oleic acid or an oleate salt, in a ratio of at least 3 oleic acid or oleate salt molecules per peptide molecule. Either the first or second chemotherapeutic agent for use in cancer therapy, for use in conjunction with the other chemotherapeutic agent, pharmaceutical compositions related thereto, and method of treatment.